Editorials keratinization using monoclonal antibodies against keratins and prekeratins.
One of the pioneer workers in monoclonal antibodies, Patrick Kung working with Ortho Pharmaceuticals in Raritan, New Jersey, pro-. duced the now widely used series of mouse monoclonal antibodies against T cell differentiation antigens, the OKT (Ortho, Kung, T cell) antibodies (Kung et al. 1979) . The OKT series of antibodies were produced in mice, using peripheral human T cells and human thymocytes as the immunogens. The antigens recognized by these antibodies are acquired and lost in a recognized sequence (Reinherz et al. 1980 ) and using these antibodies, T cell differentiation can be traced from the earliest intrathymic precursor, the prothymocyte, to functional circulating T helper and T suppressor cells.
The main Ortho antibodies in use are as follows:
OKTIO is present on all thymocytes and is lost when T cells are released into the circulation. Immunoincompetent cortical thymocytes acquire reactivity with OKT4, OKT6, OKT8 and, with maturation, migrate to the thymic medulla where immunocompetent medullary thymocytes lose reactivity with OKT6 and acquire reactivity with OKTl and OKT3.With release into the peripheral circulation the T cells either lose OKT4 reactivity to become suppressor T cells (OKTl, OKT3 OKT8 reactive) or lose OKT8 to become helper T cells (OKTl; OKT3 and OKT4 reactive). In normal adult individuals, 73 ±7% mononuclear cells are T cells: 48 ± 18% are T helper cells and 25 ± 13% are T suppressor cells. The helper/suppressor ratio is approximately 2.2 and this parameter has been used in many studies to demonstrate postulated· immunological disturbances in patients with various diseases. Unfortunately, although we can now measure the helper/suppressor ratio, there are few diseases in which we know how to interpret this result or how to manage the patient if it is abnormal.
Monoclonal antibodies in dermatology
The last decade has witnessed enormous advances in our knowledge of the immune system. One of the most important factors contributing to this influx of knowledge has been the discovery by Kohler & Milstein (1975) of the hybridoma technique of producing monoclonal antibodies. This revolutionary technique involves the artificial fusion of the nuclear material of two cells. One cell is a normal B lymphocyte sensitized to an antigen, and the second is a cell from a cultured long-term myeloma cell line. The resulting tetraploid hybrid cell acquires the characteristics of both parent cells, gaining an antibody specificity from the 8 cell and immortality from the myeloma cell. This technique has the potential to produce large quantities of a single antibody with a single specificity. The technique has already realized many goals previously unattainable using conventional heterologous antisera and has brought within our grasp the 'Holy Grail' of applied immunology, the tumour-associated antigen.
There are, however, many practical problems encountered in the production and application of monoclonal antibodies. This is exemplified by the antibodies raised against cell surface antigens. Each monoclonal antibody is totally specific for a single antigenic site, but the antigenic site is not necessarily unique to anyone cell population. Screening of antibodies must, therefore, be exhaustive. The second problem with these antibodies directly relates to their high specificity. Monoclonal antibodies react with only a single antigen and the binding of the antibody to the cell will depend on the density of the antigen on the cell surface. If an antigen is only sparsely represented on the cell, only very sensitive techniques such as radioimmunoassay can be used to identify the cell. Techniques such as immunofluorescence on cell suspension or tissue section may be unsuitable. In addition, any manipulation that reduces the availability of the antigen to the antibody, such as fixation, may obliterate recognizable binding.
In dermatology, as in other branches of medicine, monoclonal antibodies are having a profound impact. The availability of sp~i fi c monoclonal antibodies to T cell subpopulatlons and Langerhans' cells has focused interest on the study of these cells. More recently, other centres have concentrated on the investigation of In dermatology the Ortho antibodies have been used to examine the circulating lymphocytes in patients with a large number of different dermatoses. Only in cutaneous T cell lymphoma (CTCL), however, has this proved to be of diagnostic value. In CTCL (including mycosis fungoides and Sezary syndrome) the malignant lymphocyte has been shown to express the mature helper T cell phenotype -OKTI, OKT3, OKT4 reactive . In patients with all clinical stages of CTCL there is an expansion of helper T cells in the peripheral circulation (Laroche & Bach 1981) and this may be of diagnostic value when investigating a patient with suspected early CTCL. In such patients, the clinical presentation may be the only criterion on which to base a diagnosis, as the histology of the skin lesion may be nonspecific.
In patients with the leukaemic phase of CTCL (Sezary syndrome) these antibodies will confirm the helper T cell phenotype of the malignant circulating cells. It should be stressed here that erythroderma, which is one of the cardinal features of Sezary syndrome, is occasionally observed in patients with B cell tumours (Nicolis & Helwig 1973) . In addition, patients with CTCL may develop leukaemias of other cell types. Lofgren et al. (1978) reported monomyelocytic leukaemia developing in a patient with CTCL, and one patient we investigated with typical CTCL both clinically and histologically' developed a leukaemia with the phenotype OKTI-, OKT4-, OKTS-, OKM (monocyte specific)+,showing this to be a monocytic or monomyelocytic leukaemia. The treatment of B cell, T cell and monomyelocytic leukaemia is very different and the need to be able accurately to type the cells is obvious.
In one recent study of 96 patients with CTCL, the OKT series of antibodies were used to examine the T cell phenotype present in the cutaneous cellular infiltrate (Chu et al. I982b) . The results were disappointing as no single diagnostic criterion could be found which would allow the differentiation of CTCL from other dermatoses. The study did, however, reveal two diagnostic features in a small population of patients with CTCL: (I) the differentiationalloss of the OKTI antigen by tumour cells, and (2) the presence of immature T cells, expressing OKT4 and OKT8 antigens simultaneously.
A major breakthrough in the diagnosis and treatment of CTCL has come from the production by Carole Berger at Columbia Presbyterian Hospital in New York of a series of monoclonal antibodies, using leukaemic cells from a patient with CTCL as the immunogen (Berger et al. 1981) .
Two of these antibodies designated BE1 and BE2 are not reactive with normal mononuclear cells, but are reactive with circulating cells in patients with CTCL. The tumour-specific antigen? Perhaps. Both antibodies are reactive with EB virus transformed B cells and with a small number of long-term T cell lines. What these antigenic sites represent is open to speculation, but with increasing interest in the possibility of a viral aetiology of CTCL (Poiesz et al. 1980 ) they may represent viral associated antigens.
Studies using these antibodies in the investigation of the circulating lymphocytes of patients with CTCL have identified cells reactive with one or both antibodies, in even the earliest clinical stages of the disease. They have only been applied to the examination of tissue sections in a very limited study but have given promising results.
In dermatology, monoclonal antibodies have also proved valuable in the study of the Langerhans' cell. Langerhans' cells are an immigrant population of dendritic epidermal macrophages which have been shown to have an important role in the initiation of contact allergic sensitization and may act as the target cell in allogeneic graft rejection. Study of this cell has been hampered by the lack of.specific identifying markers. Ultrastructurally, the cell contains a specific organelle, the Birbeck granule (Birbeck et al. 1961) which is considered to be the only feature unique to the cell. Immunological markers of Langerhans' cells such as Fe receptors. C 3b receptors, Ia antigens, are all shown by other mononuclear cells. In 1981, Ellen Fithian first showed that OKT6, the antibody reactive with cortical thymocytes, also reacted with dendritic Ia positive epidermal cells (Fithian et al. 1981) . Subsequently OKT6 was shown by immunoelectronmicroscopy to identify both Langerhans' cells and the putative Langerhans' cell precursor, the indeterminate cells (Chu et al. I982a) . These studies represent a significant landmark in Langerhans' cell research, as the only other normal cell population reactive with OKT6 is the intrathymic cortical thymocyte. OKT6 can thus be used accurately to identify Langerhans' cells in tissue sections and can be used to prepare pure celI suspensions of Langerhans' celIs using the fluorescence activated cell sorter for in vitro investigation of Langerhans' cell function. OKT6 has also been shown to react with the malignant cells of histiocytosis X and is of obvious diagnostic value in this group of patients.
Two large areas in which monoclonal antibodies are being produced and intensively investigated are in keratinization and melanomas.
Monoclonal antibodies against keratin and prekeratins may eventually allow the differentiation of different keratinizing disorders, such as the ichthyoses, and will certainly add to our knowledge of keratinization. Work on these antibodies is still, however, embryonic but is obviously very exciting.
Monoclonal antibodies against melanoma cells are being intensively investigated (Carrel et al. 1980) . Many of the monoclonal antibodies produced against melanoma cells are directed against the HLA DR antigen, but many seem to be melanoma celJ-specific. No single common melanoma antigen has, however, been identified. The use of such antibodies will allow the differentiation of melanomas from active junctional nevae and other pigmented tumours, and may ultimately be of therapeutic value.
The greatest theoretical value of immunotherapy is in malignant disease but, until the advent of the hybridoma method of producing antibodies, was impractical because of the lack of specificity of existing heterologous antibodies. Preliminary attempts at immunotherapy in patients with CTCL using heterologous antibodies were disappointing (Edelson et al. 1979) . In these clinical studies anti thymocyte globulin (ATG) was used parenterally in the treatment of patients with advanced CTCL. This antiserum, however, attacked not only the malignant T cel1s but also normal T celJs, with a probable reduction of the patient's own immune reaction to the malignant cel1s. The malignant T ceIls were also capable of modulating the antigen recognized by the antibody, with subsequent loss of reactivity with the antibody and the emergence of even more malignant subclones of T ceIls. The patients thus initialJy responded with reduction of their skin disease, diminution in the size of involved lymph nodes and reduction in the circulating T cel1 Count. The remissions, however, were only partial and short-lived, and the disease activity often accelerated folJowing treatment, with a rapidly fatal outcome.
Recently, Miller & Levy (1981) have used the monoclonal antibody OKT3 in the treatment of CTCL, with once again initial1y good responses but ultimately disappointing results. OKT3 has the advantage over ATG of being a pure antibody with a single specificity and being easy to raise in large quantities. It does, however, share many of the problems of the ATG and may in some respects be less effective. OKT3 is present on meduIlary thymocytes and all circulating T cells; as with ATG, its effect on the T cel1 population will be nonspecific as it will not selectively attack the malignant T cells. In addition, because OKT3 is specific for a single antigenic site, modulation of the antigen by the cell will be a more serious problem. With modulation and eventually suppression of the <?KT3 antigen by the cell, further treatment with OKT3 may accelerate growth rate as a result of immunosuppression. This approach would thus seem to be of little fundamental advantage over the previous attempts with ATG.
The study of Miller & Levy (1981) did, however give valuable information about the theoreticai problems of injecting foreign protein into patients. These are allergic phenomena, such as anaphylaxis and immune complex vasculitis, and the production by the patient of blocking antibodies. In Miller and Levy's study aIlergic phenomena were not a feature, but blocking, antimouse antibodies were produced by some patients and resulted in the failure of treatment of at least one patient.
One major problem in using this form of immunotherapy is the capacity of the patient to destroy or dispose of cells attacked by the antibody. Such cel1s may be destroyed by complement fixation or by sequestration and destruction by the reticuloendothelial system. There is a limit to the capacity of both systems and if a large tumour load is present these may be quickly saturated.
In theory, the production of monoclonal antibodies specifically against tumour cells will allow the selective killing of tumour cells without the immune suppression brought about by ATG or OKT3. Many of the .problems of immunotherapy may also be overcome by the use of immunochemotherapy. Antibodies can be tagged with chem~therapeutic agents or radioisotopes, and the action of these agents directed selectively at the tumour cells without the usual bone marrow depression seen with conventional chemo-or radiotherapy. With more efficient killing of the cells, modulation of the antigen and the formation of blocking antibodies may become less relevant.
Monoclonal antibodies still represent an enormous source of untapped resources. Many of the existing monoclonal antibodies are reactive with antigens to which heterologous antisera are already available -anti-immunoglobulin, anticomplement, etc. Monoclonal antibodies however, have the potential to recognize a vast range of antigens that will ultimately be of enormous diagnostic and therapeutic value in all fields of medicine.
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Percutaneous removal of renal stones
Urolithiasis in Western communities has a high incidence, afflicting one in every 10 males before the age of 60. Furthermore, recurrence is reported in some series to be as high as 70% (Williams 1963) . The majority of these are calcium oxalate stones, and therefore much research has been devoted to the factors which predispose to the crystallization of calcium oxalate from urine (Finalyson 1974) and to measures designed to reduce the risk of recurrence. It is generally agreed that the primary objective of medical and surgical treatment is to clear the urinary tract of stones and thereafter to institute measures to lower the concentration of calcium and oxalate ions in the urine. This is usually done by increasing the urine volume and by dietary measures but. also to a lesser degree by drug therapy. 0141-0768/83/0 I0004-02/$0 1.00/0
Clearance of the urinary tract of stones less than 5 mm in diameter is usually by their spontaneous passage. Larger stones mostly require operi operations on the kidney or ureter. unless the stone is lodged in the lower ureter when extraction with a Davis loop or Dormia basket passed through a cystoscope is the standard procedure.
Urology is, however. now on the threshold of major changes in the surgical management of stone disease. for advances in radiological techniques which have already been applied to the removal of stones retained in the biliary passages are being modified so that renal stones can be removed with instruments introduced into the kidney by puncturing it from the back.
Nephroscopic removal of a renal stone was first described by Rupel & Brown in 1941, but only recently have radiologists developed techniques for introducing small tubes ... directly into renal calyces (Fernstrom & Johansson 1976) . The track of the tube can be dilated and a nephroscope introduced, but the lumen is still relatively smalI and only tiny stones can be removed through it. This limiting factor is now being overcome by the introduction of devices through the nephroscope to fragment larger stones and so facilitate their removal.
In the 1950s the Russian, Yutkin (Watson 1970), described a new method for fragmenting bladder stones, referred to as electrohydraulic lithotripsy (Urat I). This relied upon the direct application to the stone of a mechanical shock wave induced by an underwater spark produced by a condenser discharge. It was not popular because occasionally bladder injuries occurred (Pelander & Kaufman 1980) , and because other workers (Lamport & Newman 1955) had introduced a technique using ultrasonic vibrations which appeared to be considerably safer, though slower, in breaking up the stone.
Ultrasonic generators consist of quartz crystals which transform electrical into mechanical energy. The frequencies used are between 23 and 27 kHz. For this work the ultrasonic generator is perforce close to the head of the surgeon and it is mandatory that strict criteria be adopted to ensure that the operator is not overexposed to the ultrasound and harmonics of the fundamental frequency. Whilst the hazards of industrial ultrasound have been described (Acton & Hill 1977), there is some fear that the implications are not yet fully understood. Furthermore, there appears to be wide variation in the output of different quartz crystals.
The introduction of both electrohydraulic and ultrasonic devices into the kidney have now been successfully undertaken -the latter being probably safer and less likely to cause stone fragments to become embedded. With both
